首页> Journal of diabetes> Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.

Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.

导出 OA

翻译打印收藏纠错

第一作者： Li,Liu

第一单位： Beijing Hospital, Beijing, China.

作者： Li,Liu ^[1] ; Zhifeng,Cheng ^[2] ; Lianwei,Wang ^[3] ; Lili,Zhang ^[4] ; Shunbin,Li ^[5] ; Shu,Li ^[6] ; Shuguang,Pang ^[7] ; Qifu,Li ^[8] ; Fang,Bian ^[9] ; Junling,Gu ^[10] ; Jie,Shen ^[11] ; Liujun,Fu ^[12] ; Baiping,Sun ^[13] ; Yanyan,Zhao ^[13] ; Changlin,Dou ^[13] ; Zhaoyang,Zeng ^[14] ; Lixin,Guo ^[1]

作者单位： Beijing Hospital, Beijing, China. ^[1] The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. ^[2] Zhumadian Central Hospital, Zhumadia, Henan, China. ^[3] Jincheng Hospital, Jinchen, Shanxi, China. ^[4] Huzhou Central Hospital, Zhejiang, China. ^[5] Huizhou Central Hospital, Huizhou, Guangdong, China. ^[6] Jinan Central Hospital, Jinan City, Shandong, China. ^[7] The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. ^[8] People's Hospital of Cangzhou, Cangzhou, Hebei, China. ^[9] Second People's Hospital of Yibin, Yibin, Sichuan, China. ^[10] Shunde Hospital of Southern Medical University, Foshan, Guangdong, China. ^[11] The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China. ^[12] Shandong Boan Biotechnology Co. Ltd, Yantai, China. ^[13] Yichang Central People's Hospital, Yichang, Hubei, China. ^[14]

关键词 HbA1c biosimilar dulaglutide safety